Long Noncoding RNA PVT1 Promotes EMT and Cell Proliferation and Migration Through Downregulating p21 in Pancreatic Cancer Cells

Abstract

Background and Aim:Long noncoding RNA-plasmacytoma variant translocation 1 is identified to be highly expressed and exhibits oncogenic activity in a variety of human malignancies, including pancreatic cancer. However, little is known about the overall biological role and mechanism of plasmacytoma variant translocation 1 in pancreatic cancer so far. In this study, we investigated the effect of plasmacytoma variant translocation 1 on pancreatic cancer cell proliferation and migration as well as epithelial–mesenchymal transition.Methods:Pancreatic cancer tissue specimens and cell line were used in this study, with normal tissue and cell line acting as control.Results:It showed that plasmacytoma variant translocation 1 expression was significantly upregulated in pancreatic cancer tissues or cell line compared to normal groups. Plasmacytoma variant translocation 1 downregulation significantly inhibited zinc finger E-box-binding protein 1/Snail expression but promoted p21 expression, and it also inhibited the cell proliferation and migration. Additionally, p21 downregulation enhanced, and p21 overexpression repressed, zinc finger E-box-binding protein 1/Snail expression and cells proliferation in PANC-1 cells. However, p21 downregulation reversed the effect of plasmacytoma variant translocation 1 downregulation on zinc finger E-box-binding protein 1/Snail expression and cell proliferation and migration.Conclusion:Plasmacytoma variant translocation 1 promoted epithelial–mesenchymal transition and cell proliferation and migration through downregulating p21 in pancreatic cancer cells.

Long non‐coding RNA PVT1: Emerging biomarker in digestive system cancer

“…Other several studies also supported the PVT1 as an important biomarker. As shown in many previous studies, Wu et al noted that PVT1 expression was drastically found to be up‐regulated in PC tissues or cell lines in comparison with normal groups. They also found PVT1 stimulates EMT, cell proliferation, along with migration via down‐regulating p21 in PC cells.…”

Overexpression of LncRNA PVT1 Predicts Advanced Clinicopathological Features and Serves as an Unfavorable Risk Factor for Survival of Patients with Gastrointestinal Cancers

“…A total of 2585 participants were included with a maximum sample size of 593 and a minimum sample size of 30. Among the 15 articles, the digestive system malignancies assessed in these studies included esophageal carcinoma (2 articles) [39, 44], gastric cancer (6 articles) [22, 33, 38, 40-42], colorectal cancer (2 articles) [20, 37], hepatocellular carcinoma (2 articles) [21, 34], pancreatic cancer (3 articles) [35, 36, 43]. Among the eligible articles, one came from Japan [20], one came from Portugal [36] and the rest of 13 articles were came from China [21-22, 33-35, 37-44].…”

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

“…Inhibition of the expression of PVT1 in cancer cells reduces the expression of vimentin, while it enhances the expression of E-cadherin [98]. PVT1 downregulates the expression of p21, while p21 downregulates the expression of Snail [127]. Moreover, PVT1 can upregulate Twist1 by adsorption of miR-186-5p to promote the EMT [128].…”